On this week’s episode of Biotech Hangout, CEO of Bellus Health (announced this week that GSK is acquiring for $2B), Roberto Bellini, joins hosts Daphne Zohar, Tim Opler, Dawn Bell, Sam Fazeli and Brad Loncar. The group discusses the week’s deals and financings, data and broader themes of innovation. Roberto shares his personal experience going through an acquisition and what it took for his company to get to that point from a TSK listed microcap valued at ~$15M to a $2B success story, his thoughts on innovation taking many different forms and the pros and cons of single-asset companies. The hosts also deep dive into AACR data, highlighting Lily’s KRAS data & Moderna’s vaccine data and touch on how policy is affecting our industry, with a focus on some new bills seeking to improve how R&D expenses are deducted. *This episode aired on April 21, 2023*
Disclosures from Josh Schimmer:
